Robust metabolic pipeline focused on NASH and rare metabolic diseases

Poxel has two mid-stage products: PXL065 (deuterium-stabilized R-pioglitazone) targeting NASH, which met its primary endpoint in a streamlined Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, exclusively focused on rare diseases.

The Company also has one product, TWYMEEG® (Imeglimin), approved in 2021, now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma, and expects to receive royalties and sales-based payments.

VIEW OUR CANDIDATES

Latest News

Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

The Company announced today the extension of the cash runway through Q2 2025 based upon a debt restructuring agreement and a new equity-linked financing facility Restructuring of the Company’s debt postpones…

Read this Press Release: Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility

Restructuring of the Company’s debt postpones initiation of repayments to Q1 2025, to be repaid with positive net royalty1 flow to Poxel anticipated to start in Sumitomo Pharma’s FY20242 based on the strong…

Read this Press Release: Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility

Poxel will Report its 2022 Full Year Results on March 23, 2023

LYON, France--(BUSINESS WIRE)-- Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with…

Read this Press Release: Poxel will Report its 2022 Full Year Results on March 23, 2023
Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

An expertise focused on targeting mitochondrial dysfunction

The Company’s most advanced clinical products - PXL065, PXL770 and Imeglimin (now commercialized in Japan) - address significant targets in the energy metabolism pathways

View Our Candidates
An expertise focused on targeting mitochondrial dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams combines the know-how and experience to successfully develop products, such as Imeglimin, which is marketed by our partner Sumitomo Pharma in Japan since 2021.

Meet Our Team
Backed by Strong Leadership